[Aztreonam versus tobramycin in acute pyelonephritis. A comparative study].
We performed a comparative study between the monobactam antibiotic aztreonam and the aminoglycoside tobramycin in patients diagnosed as having acute pyelonephritis. The respective doses were 1 gr. IM daily for 7 days, and 100 mgr. IM q 12 h for the same period of time. Clinically, 100% of uncomplicated acute pyelonephritis and 87.5% of complicated infections cured with aztreonam. Tobramycin achieved an 80% cure rate for both types of infections. Microbiologically aztreonam was effective in all uncomplicated acute pyelonephritis, and in 69.56% of the complicated cases (overall microbiological cure rate = 78.7%). The therapeutic failures were ascribable to infections from S. faecalis, an organism naturally resistant to aztreonam. Thus, the microbiological cure rate was 84.2% in complicated pyelonephritis from organisms sensitive to this antimicrobial. The microbiological cure rate for tobramycin was 70% in acute uncomplicated, and 80% in complicated infections. We observed a good clinical and biological tolerance to both antimicrobials. No side effects were observed. Serum and blood biochemical analyses, and coagulation tests revealed no changes.
Gallego
J
J
Jiménez Cruz
J F
JF
Gobernado
M
M
Llopis
B
B
Vidal
J
J
Server
G
G
Ruiz
J L
JL
David Vera
C
C
D000208:Acute Disease; D000328:Adult; D000368:Aged; D001398:Aztreonam / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011704:Pyelonephritis / Q000188:drug therapy*; D014031:Tobramycin / Q000627:therapeutic use*
D001398:Aztreonam; D014031:Tobramycin
Aztrenonam versus tobramicina en pielonefritis agudas. Estudio comparativo.